An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice

Michelle E. McClements, Alun R. Barnard, Mandeep Singh, Peter Charbel Issa, Zhichun Jiang, Roxana A. Radu, Robert E. MacLaren

Research output: Contribution to journalArticle

Abstract

The recent approval in the United States of the first adeno-associated viral (AAV) vector for the treatment of an inherited retinal degeneration validates this approach for the treatment of many other diseases. A major limiting factor continues to be the size restriction of the AAV transgene at under 5 kb. Stargardt disease is the most prevalent form of recessively inherited blindness and is caused by mutations in ABCA4, the gene that codes for ATP-binding cassette transporter protein family member 4, which has a coding sequence length of 6.8 kb. Dual vector approaches increase the capacity of AAV gene therapy, but at the cost of substantially reduced levels of target protein, which may be insufficient to achieve a therapeutic effect. Here we show that the efficacy of recombination of dual vectors is dependent on the length of DNA overlap between two transgenes. With optimized recombination, full-length ABCA4 protein is expressed in the photoreceptor outer segments of Abca4 -/- mice at levels sufficient to reduce bisretinoid formation and correct the autofluorescent phenotype. These observations support a dual vector approach in future clinical trials using AAV gene therapy to treat Stargardt disease.

Original languageEnglish (US)
Pages (from-to)590-600
Number of pages11
JournalHuman gene therapy
Volume30
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Viral Genes
Transgenes
Phenotype
Genetic Therapy
Genetic Recombination
Retinal Degeneration
Proteins
ATP-Binding Cassette Transporters
Therapeutic Uses
Blindness
Clinical Trials
Mutation
DNA
Therapeutics
Genes
Stargardt disease 1

Keywords

  • ABCA4
  • adeno-associated virus
  • dual vector
  • gene therapy
  • Stargardt disease

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

McClements, M. E., Barnard, A. R., Singh, M., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019). An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice Human gene therapy, 30(5), 590-600. https://doi.org/10.1089/hum.2018.156

An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice . / McClements, Michelle E.; Barnard, Alun R.; Singh, Mandeep; Charbel Issa, Peter; Jiang, Zhichun; Radu, Roxana A.; MacLaren, Robert E.

In: Human gene therapy, Vol. 30, No. 5, 01.05.2019, p. 590-600.

Research output: Contribution to journalArticle

McClements, ME, Barnard, AR, Singh, M, Charbel Issa, P, Jiang, Z, Radu, RA & MacLaren, RE 2019, ' An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice ', Human gene therapy, vol. 30, no. 5, pp. 590-600. https://doi.org/10.1089/hum.2018.156
McClements, Michelle E. ; Barnard, Alun R. ; Singh, Mandeep ; Charbel Issa, Peter ; Jiang, Zhichun ; Radu, Roxana A. ; MacLaren, Robert E. / An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice In: Human gene therapy. 2019 ; Vol. 30, No. 5. pp. 590-600.
@article{41ce6ffaabe6432fa3ca58a21a6ffcdf,
title = "An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice",
abstract = "The recent approval in the United States of the first adeno-associated viral (AAV) vector for the treatment of an inherited retinal degeneration validates this approach for the treatment of many other diseases. A major limiting factor continues to be the size restriction of the AAV transgene at under 5 kb. Stargardt disease is the most prevalent form of recessively inherited blindness and is caused by mutations in ABCA4, the gene that codes for ATP-binding cassette transporter protein family member 4, which has a coding sequence length of 6.8 kb. Dual vector approaches increase the capacity of AAV gene therapy, but at the cost of substantially reduced levels of target protein, which may be insufficient to achieve a therapeutic effect. Here we show that the efficacy of recombination of dual vectors is dependent on the length of DNA overlap between two transgenes. With optimized recombination, full-length ABCA4 protein is expressed in the photoreceptor outer segments of Abca4 -/- mice at levels sufficient to reduce bisretinoid formation and correct the autofluorescent phenotype. These observations support a dual vector approach in future clinical trials using AAV gene therapy to treat Stargardt disease.",
keywords = "ABCA4, adeno-associated virus, dual vector, gene therapy, Stargardt disease",
author = "McClements, {Michelle E.} and Barnard, {Alun R.} and Mandeep Singh and {Charbel Issa}, Peter and Zhichun Jiang and Radu, {Roxana A.} and MacLaren, {Robert E.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1089/hum.2018.156",
language = "English (US)",
volume = "30",
pages = "590--600",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 -/- Mice

AU - McClements, Michelle E.

AU - Barnard, Alun R.

AU - Singh, Mandeep

AU - Charbel Issa, Peter

AU - Jiang, Zhichun

AU - Radu, Roxana A.

AU - MacLaren, Robert E.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The recent approval in the United States of the first adeno-associated viral (AAV) vector for the treatment of an inherited retinal degeneration validates this approach for the treatment of many other diseases. A major limiting factor continues to be the size restriction of the AAV transgene at under 5 kb. Stargardt disease is the most prevalent form of recessively inherited blindness and is caused by mutations in ABCA4, the gene that codes for ATP-binding cassette transporter protein family member 4, which has a coding sequence length of 6.8 kb. Dual vector approaches increase the capacity of AAV gene therapy, but at the cost of substantially reduced levels of target protein, which may be insufficient to achieve a therapeutic effect. Here we show that the efficacy of recombination of dual vectors is dependent on the length of DNA overlap between two transgenes. With optimized recombination, full-length ABCA4 protein is expressed in the photoreceptor outer segments of Abca4 -/- mice at levels sufficient to reduce bisretinoid formation and correct the autofluorescent phenotype. These observations support a dual vector approach in future clinical trials using AAV gene therapy to treat Stargardt disease.

AB - The recent approval in the United States of the first adeno-associated viral (AAV) vector for the treatment of an inherited retinal degeneration validates this approach for the treatment of many other diseases. A major limiting factor continues to be the size restriction of the AAV transgene at under 5 kb. Stargardt disease is the most prevalent form of recessively inherited blindness and is caused by mutations in ABCA4, the gene that codes for ATP-binding cassette transporter protein family member 4, which has a coding sequence length of 6.8 kb. Dual vector approaches increase the capacity of AAV gene therapy, but at the cost of substantially reduced levels of target protein, which may be insufficient to achieve a therapeutic effect. Here we show that the efficacy of recombination of dual vectors is dependent on the length of DNA overlap between two transgenes. With optimized recombination, full-length ABCA4 protein is expressed in the photoreceptor outer segments of Abca4 -/- mice at levels sufficient to reduce bisretinoid formation and correct the autofluorescent phenotype. These observations support a dual vector approach in future clinical trials using AAV gene therapy to treat Stargardt disease.

KW - ABCA4

KW - adeno-associated virus

KW - dual vector

KW - gene therapy

KW - Stargardt disease

UR - http://www.scopus.com/inward/record.url?scp=85062015155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062015155&partnerID=8YFLogxK

U2 - 10.1089/hum.2018.156

DO - 10.1089/hum.2018.156

M3 - Article

C2 - 30381971

AN - SCOPUS:85062015155

VL - 30

SP - 590

EP - 600

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 5

ER -